case 4: assessing risk for transformation to aml
Published 4 years ago • 75 plays • Length 3:42Download video MP4
Download video MP3
Similar videos
-
5:43
case 4: high-risk de novo aml
-
2:42
case 1: transformation of myelofibrosis to aml
-
3:21
case 4: additional considerations in high-risk de novo aml
-
4:36
case 4: risk factors and genetic abnormalities of mpn
-
7:52
case 4: treating aml with hma/venetoclax
-
9:06
case 4: treatment considerations for high-risk and standard-risk r/r myeloma
-
4:15
case 2: selecting a targeted therapy for aml with mrc
-
6:46
case 2: aml with myelodysplasia-related changes
-
3:20
thrombosis, myelofibrosis, and acute myeloid leukemia
-
1:48
case presentation of therapy-related aml
-
5:19
case 2: cpx-351 treatment for aml with mrc
-
5:55
case 4: observations of hma/venetoclax in trials
-
4:55
the challenges in aml-mrc
-
2:00
aml: a case of myelodysplasia-related changes
-
6:39
presentation and criteria for aml-mrc
-
3:17
case 1: assessing risk in cll
-
3:58
primary myelofibrosis therapeutic response assessment
-
2:07
what is meant by “targeted therapy” for aml?
-
3:22
case-based overview: newly diagnosed acute myeloid leukemia